Arbeitsgruppe Endokrine Tumoren - geschlossene Studien
| Malignes Phäochromozytom / Paragangliom – palliative Therapie | ||||
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| First International Randomised Study in MAlignant Progressive Phaeochromocytoma and Paraganglioma (FIRST-MAPPP) – Sunitinib vs. Placebo | ||||
| ---Rekrutierung beendet--- | ||||
| Nebennierenkarzinom, "salvage therapy" | ||||
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-ENC-0114: Phase-I-Studie zur Sicherheit und Verträglichkeit von ATR-101 bei Nebennierenrindenkarzinom | ||||
| ---Rekrutierung beendet--- | ||||
| Metastasiertes Schilddrüsenkarzinom - Zweitlinientherapie |
||||
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-ENC-0316/ass: A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy ( EORTC protocol 1209-EnTF) | ||||
| ---Rekrutierung beendet--- | ||||
| Endocrine malignancies refractory to standard treatment, 2nd/3rd line | ||||
| AIO-Studie | zur Studie | |||
| AIO-YMO/ENC-0116: Immune modulation with MEDI-4736 (Durvalumab) and Tremelimumab in refractory endocrine malignancies – a phase II trial (iM-REM) 20 | ||||
| ---Studie wurde nicht durchgeführt--- | ||||
| Fortgeschrittenes Schilddrüsenkarzinom | ||||
| AIO-assoziierte Studie | zur Studie | |||
| Open label Phase I Study of Everolimus (RAD001) plus Doxorubicin in advanced progressive and refractory thyroid cancer (Thyradox-Trial) |
||||
| ---Rekrutierung beendet, bzw. im Follow up--- | ||||
| AIO-assoziierte Studie | zur Studie | |||
| Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer (PANTHERA-Trial) |
||||
| AIO-assoziierte Studie | zur Studie | |||
| Randomisierte, doppelblinde, Placebo-kontrollierte Phase II- Studie zur Beurteilung von Wirksamkeit und Sicherheit von Sorafenib bei Patienten mit fortgeschrittenem (rezidivierendem, anhaltendem und/oder metastasiertem) medullärem Schilddrüsenkarzinom (SUMMIT). |
||||
| AIO-Joint-Studie | zur Studie | |||
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma | ||||
| AIO-Joint-Studie | zur Studie |
|||
| First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) | ||||
| AIO-Joint-Studie | zur Studie |
|||
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma | ||||
| AIO-Joint-Studie | zur Studie |
|||
| Sunitinib In Refractory Adrenocortical Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC) | ||||
| LETZTE AKTUALISIERUNG DIESER SEITE AM: 14.06.2018 |